Trials / Completed
CompletedNCT00185185
Olmesartan Medoxomil in Atherosclerosis
Multi-Centre Olmesartan Atherosclerosis Regression Evaluation (MORE)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 165 (actual)
- Sponsor
- Sankyo Pharma Gmbh · Industry
- Sex
- All
- Age
- 35 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a study in hypertensive patients with atherosclerosis and increased cardiovascular risk. The efficacy of olmesartan medoxomil on atherosclerosis is measured.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olmesartan medoxomil | |
| DRUG | Atenolol | |
| DRUG | Hydrochlorothiazide | tablets |
| DRUG | olmesartan medoxomil | tablets |
| DRUG | atenolol | tablets |
Timeline
- Start date
- 2001-11-01
- Completion
- 2006-02-01
- First posted
- 2005-09-16
- Last updated
- 2007-12-14
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00185185. Inclusion in this directory is not an endorsement.